Canadian Journal of Gastroenterology and Hepatology / 2018 / Article / Tab 5

Research Article

Efficacy and Safety of Immunosuppressive Therapy for PBC–AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study

Table 5

Liver-related adverse events in the two groups.

VariablesUDCA-only group (N=14)UDCA+IS group (N=14)P value

Adverse events9/14(64.3%)2/14(14.3%)0.018
Severe ascites4(28.6%)1(7.1%)0.326
Variceal bleeding1(7.1%)0>0.999
Liver failure4(28.6%)1(7.1%)0.596
Transplantation/liver-related death4/14(28.6%)1/14(7.1%)0.326

Note. UDCA, ursodeoxycholic acid; IS, immunosuppressants.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.